Moderna (MRNA) shares tumbled 20% to $138 on Thursday, erasing a portion of the historic gains from the previous session when the biotech firm reported positive late-stage data for its personalized mRNA cancer vaccine. The sharp pullback came as investors locked in profits and analysts weighed whether the stock's valuation had run ahead of the clinical breakthrough.
The selloff followed a more than doubling of Moderna's share price on August 19, after the company and partner Merck announced that their Phase 3 INTerpath-001 study of the investigational therapy intismeran autogene met its primary and key secondary endpoints. The trial enrolled more than 1,100 patients with high-risk melanoma, marking the first successful large-scale late-stage cancer study for an mRNA-based treatment.
The results represent a significant step for Moderna as it seeks to diversify beyond its established respiratory vaccine franchise. However, the magnitude of the rally left the stock vulnerable to profit-taking, and several analysts noted that the market may have already priced in much of the optimism.
Analysts raise targets but remain cautious
Following the data, a number of Wall Street firms updated their price targets. RBC Capital lifted its target to $130 from $45 while keeping a Sector Perform rating. Bank of America upgraded Moderna and raised its target to $170 from $40, with analyst Alec Stranahan calling the results "a watershed moment for Moderna" that could help the company reduce its reliance on infectious disease products and address persistent capital concerns.
Still, Stranahan emphasized that key questions remain about how the combination therapy performs against Merck's Keytruda alone. He noted that a hazard ratio of 0.6 to 0.7 at an upcoming medical meeting, such as the European Society for Medical Oncology conference, would be needed to make the outlook more positive. His comments suggest that investors may require additional clinical data before assigning further value to Moderna's cancer program.
UBS also maintained a Hold rating while raising its price target to $150 from $50. The revised targets from RBC and Bank of America were both below Wednesday's closing price of $174.38, underscoring the uncertainty surrounding the stock's valuation after its record rally.
Valuation concerns take center stage
The gap between the new analyst targets and Moderna's post-rally price highlights the extent to which investors had already priced in expectations around the cancer vaccine. The upcoming medical presentation could serve as a key catalyst, particularly if additional data provide greater clarity on the treatment's effectiveness compared with Keytruda alone.
For now, Moderna's retreat reflects a combination of profit-taking and renewed scrutiny of valuation following an unusually large one-day gain. The broader market context also played a role, as Treasury buybacks helped ease yields and supported equities, but biotech names often give back some gains after major clinical readouts.
Investors may also be watching related moves in the sector, such as the recent surge in Tempus AI on vaccine data and the broader crypto rally fueled by short squeezes. Meanwhile, the Dow's gains on Treasury buybacks provided some support to risk assets, but Moderna's decline shows that even positive news can be overshadowed by valuation concerns.
This article is for informational purposes only and does not constitute financial advice.
